Trials / Unknown
UnknownNCT03940820
Clinical Research of ROBO1 Specific CAR-NK Cells on Patients With Solid Tumors
- Status
- Unknown
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Asclepius Technology Company Group (Suzhou) Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Immunotherapy has become the major breakthrough and the most promising treatment, with the host of development of tumor biology, molecular biology and immunology. We have developed anti-ROBO1 CAR-NK cells that can target tumor cells highly expressing ROBO1. The purpose of this study is to evaluate the safety and effectiveness of cell therapy using ROBO1 CAR-NK cells to treat solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | ROBO1 CAR-NK cells | The subject will be observed for any side effects during this time and all the adverse events will be recorded. |
Timeline
- Start date
- 2019-05-01
- Primary completion
- 2021-05-01
- Completion
- 2022-05-01
- First posted
- 2019-05-07
- Last updated
- 2019-05-07
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03940820. Inclusion in this directory is not an endorsement.